The End Fund

What it reported doing in 2024

The END Fund is a leading philanthropic community dedicated to ending six neglected tropical diseases that impact 1.65 billion people globally: intestinal worms, schistosomiasis, lymphatic filariasis, river blindness, trachoma, and visceral leishmaniasis. The END Fund efficiently puts private capital to work, advocating for neglected tropical disease programs that are innovative, integrated and cost-effective. We facilitate strong partnerships with the private sector, government partners, and local programmatic partners to collaboratively support national disease programs. This is done through a proven implementation model that is tailored to meet the needs of individual countries. The END Fund was established as a new model, the first of its kind in the neglected tropical disease field: a philanthropic fund that increases resources, coordination, and collaboration toward the goal of ending neglected tropical diseases, thereby reducing the physical, social, economic, and systemic impact of these diseases for hundreds of millions of people. Our model is designed to mobilize resources to close the neglected tropical disease funding gap through partnerships with global philanthropists and private-sector investors. By pooling funds, the END Fund helps activist-philanthropists make outsized impacts with their investments. Through collaboration with our programmatic partners, we help deliver treatment at scale, accelerate innovations that improve the efficiency of drug delivery, provide program oversight to monitor quality and impact, and bring together partners, advocates, and investors. Because we direct resources and training activities through local partners, who know the landscape and can go where international agencies cannot or will not, we operate successfully and with measurable impact in some of the world's most challenging environments due to war or instability. Our focus has always been on large-scale change and we are committed to investing in and alongside local governments, building in-country technical tools and skills, and incorporating neglected tropical diseases into national health agendas for solid local ownership. In close partnership with stakeholders across the global neglected tropical disease community, the END Fund: Identified gaps and opportunities, by understanding investment needs and gaps in funding for neglected tropical diseases, landscapes investable opportunities, and increases coordination among stakeholders. The END Fund also builds coalitions, by mobilizing and activating collaboration among country-level stakeholders, including ministries of health, programmatic partners, investors, etc. The END Fund designs programs by working with ministries of health and programmatic partners to expand data collection, mapping, and sector knowledge in order to identify compelling program opportunities. The END Fund trains partners by aiming to grow and strengthen the pool of partner organizations to assist local governments in the implementation of quality neglected tropical disease programs. The END Fund manages grants and provides technical support by conducting country program visits and provides partner support, technical assistance, and training as needed. In 2024, the END Fund supported the distribution of 247,323,479 NTD treatments with 152,630,533 people treated across 21 countries by 27 implementing partners. During the same period, 38,100 surgeries were conducted in 12 countries by 15 implementing partners and 1,198,935 health care workers trained across 24 countries by 31 implementing partners.

Financial Efficiency

• Mission deployment rate: 100%; rating input score 100
• Program expense ratio: 90.3%; rating input score 90
• Fundraising efficiency: $13.26 raised per $1 spent on fundraising; rating input score 48; 48th percentile among comparable filings

Transparency & Controls

• Consistency checks: 87.5%; rating input score 88; 2nd percentile among comparable filings
• Pay-setting controls: 5 of 6 controls in place; rating input score 83
  • Compensation committee: Pass
  • Independent consultant: Pass
  • Other Form 990s reviewed: Pass
  • Written employment contract: Missing
  • Compensation survey or study: Pass
  • Board or committee approval: Pass
• Foreign activity oversight: 3 of 8 controls in place; rating input score 38
  • Claims monitoring procedures: Pass
  • Requires narrative reports: Fail
  • Conducts field audits: Fail
  • May suspend future funding: Fail
  • Requires financial reports: Fail
  • Conducts site visits: Pass
  • Requires grant agreements: Pass
  • May require repayment: Fail
• Grant itemization coverage: 95.7%; rating input score 96; 29th percentile among comparable filings
• Major donor itemization: Yes; rating input score 100
• Related-party transparency: Limited

Accountability

• Independent voting board: 100%; rating input score 100; 77th percentile among comparable filings
• Governance controls: 9 of 9 controls in place; rating input score 100
  • Conflict-of-interest policy: Pass
  • Whistleblower policy: Pass
  • Document-retention policy: Pass
  • CEO compensation review process: Pass
  • Other executive compensation review process: Pass
  • Form 990 shared with the board: Pass
  • Board meeting minutes documented: Pass
  • Audit committee oversight: Pass
  • Independent financial-statement audit: Pass

Sustainability

• Operating margin: -18.4%; rating input score 4; 4th percentile among comparable filings
• Total-asset coverage ratio: 0.52; rating input score 19; 19th percentile among comparable filings
• Liabilities to assets ratio: 0.07; rating input score 86; 86th percentile among comparable filings
• Officer compensation ratio: 3.4%; rating input score 32; 32nd percentile among comparable filings

Growth

• Program expense growth: 18.6% per year; rating input score 100; 91st percentile among comparable filings
• Revenue growth: 14.5% per year; rating input score 100; 88th percentile among comparable filings
• Asset growth: 9.1% per year; rating input score 100; 65th percentile among comparable filings